Industry News
-
EPFL Scientists Use AAV-Mediated Partial Reprogramming to Restore Memory in Aged and Alzheimer’s Mice
Feb 10 2026 -
Gyala Therapeutics Initiates Phase I/IIa Trial of CD84-Targeting CAR-T Therapy GYA01 in AML and T-ALL
Feb 10 2026 -
AAV9-GLB1 Gene Therapy Shows Manageable Safety Profile and Potential Disease Stabilization in GM1 Gangliosidosis
Feb 10 2026 -
FDA Grants RMAT Designation to KB707, an Inhaled Gene Therapy for Advanced Lung Cancer
Feb 09 2026 -
VectorY Doses First Patient with AAV-Based TDP-43 Therapy in Phase 1/2 PIONEER-ALS Trial
Feb 09 2026 -
Solid Biosciences Aligns with FDA on Phase 3 Design for SGT-003 Gene Therapy
Feb 09 2026 -
SparingVision Completes Dosing in Phase I/II PRODYGY Trial of Gene-Agnostic AAV Gene Therapy for Retinitis Pigmentosa
Feb 09 2026 -
Lilly Acquires Orna Therapeutics for Up to $2.4B to Expand In Vivo CAR-T Portfolio
Feb 09 2026 -
FDA Rejects Regenxbio’s AAV Gene Therapy RGX-121 for Hunter Syndrome
Feb 09 2026